#ASCO17: Epizyme will hunt a quick OK for tazemetostat, despite disappointing analysts with new data
As the dust began to settle from the ASCO abstract drop last night, several analysts weighed in noting their cautious lack of optimism for Epizyme …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
